A detailed history of Cormorant Asset Management, LP transactions in Merus N.V. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 740,000 shares of MRUS stock, worth $31 Million. This represents 2.59% of its overall portfolio holdings.

Number of Shares
740,000
Previous 840,000 11.9%
Holding current value
$31 Million
Previous $49.7 Million 25.62%
% of portfolio
2.59%
Previous 3.82%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$47.19 - $58.84 $4.72 Million - $5.88 Million
-100,000 Reduced 11.9%
740,000 $37 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $4.98 Million - $7.53 Million
125,000 Added 17.48%
840,000 $49.7 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $20 Million - $37.1 Million
715,000 New
715,000 $32.2 Million
Q1 2022

May 16, 2022

SELL
$23.58 - $30.91 $2.36 Million - $3.09 Million
-100,000 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$20.0 - $32.29 $3 Million - $4.84 Million
-150,000 Reduced 60.0%
100,000 $3.18 Million
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $578,382 - $955,664
-35,096 Reduced 12.31%
250,000 $5.5 Million
Q2 2021

Aug 16, 2021

SELL
$20.0 - $25.48 $1.3 Million - $1.65 Million
-64,904 Reduced 18.54%
285,096 $6.01 Million
Q4 2020

Feb 16, 2021

SELL
$11.4 - $18.36 $903,837 - $1.46 Million
-79,284 Reduced 18.47%
350,000 $6.14 Million
Q3 2020

Nov 16, 2020

SELL
$10.57 - $16.0 $1.8 Million - $2.73 Million
-170,716 Reduced 28.45%
429,284 $5.15 Million
Q1 2020

May 15, 2020

SELL
$11.34 - $19.44 $4.54 Million - $7.78 Million
-400,000 Reduced 40.0%
600,000 $7.26 Million
Q4 2019

Feb 14, 2020

BUY
$14.08 - $18.5 $14.1 Million - $18.5 Million
1,000,000 New
1,000,000 $14.1 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.92B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.